Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00651716 · ClinicalTrials.gov registry record

T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.

Terminated
Registry status
150
Enrollment target

NCT00651716 is a clinical trial that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 150 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00651716 was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.

TERMINATED
Registry status
150 participants
Enrollment target

Study Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict whether patients undergoing donor stem cell transplant will develop acute graft-versus-host disease. PURPOSE: This clinical trial is studying T cells to see how well they help in predicting acute graft-versus-host disease in patients undergoing donor stem cell transplant.

Interventions

  • OTHER Data Collection
  • OTHER laboratory biomarker analysis
  • OTHER flow cytometry

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2006-12
Est. Completion 2019-10

Sponsor

Vanderbilt-Ingram Cancer Center

189 total trials

What the Registry Record Tells You About NCT00651716

The ClinicalTrials.gov registry entry for NCT00651716 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Data Collection is the first listed.

NCT00651716 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00651716 about?

NCT00651716 is a clinical study titled "T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant". RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict whether patients undergoing donor stem cell transplant will develop acute graft-versus-host disease. PURPOSE: This clinical trial is studying T cells to see how well they help in predicting acu...

What is the current status of trial NCT00651716?

This trial is currently terminated. The enrollment target is 150 participants. The study started on 2006-12. Estimated completion is 2019-10.

What interventions are being tested in trial NCT00651716?

The interventions under investigation include: Data Collection (OTHER), laboratory biomarker analysis (OTHER), flow cytometry (OTHER).

Who is sponsoring clinical trial NCT00651716?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.